LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
M.H.H. Schuler, K. Cuppens, T. Ploenes, M. Vanbockrijck, M. Wiesweg, K. Darwiche, A. Schramm, Brigitte Maes, B. Hegedus, Hans‐Ulrich Schildhaus, H. Hautzel, D. Theegarten, P. Baas, K. Hartemink, Bertrand Du Pont, C. Aigner
Topics & Concepts
MedicineNivolumabClinical endpointLung cancerSurgeryPopulationAdverse effectRandomized controlled trialInternal medicineCancerImmunotherapyEnvironmental healthCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging